Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

Sg, Özkan; Yazısız, Hatice; Behlül, Ahmet; Ya, Gökbelen; Borlu, Fatih; Yazısız,

doi:10.5152/eurjrheum.2017.16052

Cited by 28 publications

(32 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our secondary hypothesis was that we are able to correlate the FOI results with cardiovascular risk factors since these risk factors are well known to be speci cally high in Pso/PsA patients. (5,(9)(10)(11)(12)(13)(14)(15)(16) However, in our study, only the body weight had an in uence on the FOI results. In this respect, we did not measure the blood pressure directly before and after the FOI scan and did not do a full metabolic status on the patients.…”

Section: Discussioncontrasting

confidence: 59%

“…(7,8) Furthermore, PsA patients reveal an increased prevalence of CV risk factors such as hypertension (9,10), diabetes mellitus (6,10), hyperlipidemia (10,11) and the full metabolic syndrome. (12)(13)(14)(15)(16) Accordingly, a signi cantly increased prevalence of metabolic syndrome in patients with PsA compared to rheumatoid arthritis (RA) patients was demonstrated recently (12), although comparable in ammatory pathways can be seen in both diseases. (17) Approaches to explain these phenomena have already been explored in various studies with different focus.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of subclinical skin manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging

Schmidt

Glimm

Haugen

et al. 2020

Preprint

View full text Add to dashboard Cite

Objectives: To investigate the frequency of subclinical skin inflammation in both hands by fluorescence optical imaging (FOI) in patients with psoriasis/psoriatic arthritis (Pso/PsA) vs. rheumatoid arthritis (RA) and healthy individuals, and to correlate these findings with cardiovascular (CV) risk factors.Patients and Methods: The FOI scans were analyzed retrospectively to detect clinically invisible skin enhancement (0-3 scale) in both hands without relationship to underlying joints or blood vessels. We further characterized the FOI patterns and sorted the scans into groups based on the assumed diagnosis (Pso/PsA, RA and healthy controls), which was compared with the physician’s diagnosis. Furthermore, the associations between CV risk factors and imaging findings were investigated by regression analyses.Results: We included FOI scans of patients with Pso/PsA (n=80), RA (n=78) and healthy controls (n=25). Subclinical skin enhancement on the back of their hands was more common in Pso/PsA (72.5%) than in RA patients (20.5%) and healthy individuals (28.0%) (p<0.001). Based on the FOI pattern, the majority of patients with Pso/PsA (72.5%), RA (76.9%) and healthy controls (68.0%) were classified correctly using the physician-based diagnosis as reference (overall agreement of 74%, kappa=0.57). No CV risk factors except body weight (kg) was associated with subclinical skin enhancement (OR 1.04, 95% CI 1.02-1.06; p<0.001). Conclusion: Subclinical subdermal skin inflammation was common in Pso/PsA patients using FOI. Based on the FOI pattern, most patients with Pso/PsA and were classified with the correct diagnosis. We demonstrated an important influence of the body weight on our FOI results. FOI may be a helpful novel tool to study microcirculation in rheumatic diseases with skin involvement.

show abstract

Section: Discussioncontrasting

confidence: 59%

Section: Introductionmentioning

confidence: 99%

Detection of subclinical skin manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging

Schmidt

Glimm

Haugen

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…It is well known that metabolic syndrome is a common disorder among PsA patients (3,4). In this study, metabolic syndrome was seen in 21 patients (24.4 %), which was a lower rate than previously reported in literature (29,30).…”

Section: Discussioncontrasting

confidence: 54%

Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis

Çolak¹,

Omma²,

Sandıkçı³

et al. 2019

BLL

View full text Add to dashboard Cite

OBJECTIVES: To examine the relationship between disease activity and vaspin, neutrophil gelatinase-associated lipocalin (NGAL) and apolipoprotein levels in patients with psoriatic arthritis (PsA). BACKGROUND: Psoriatic arthritis (PsA) is a chronic infl ammatory arthritis, which is related with psoriasis. Adipokines are the mediators which play a role in metabolic homeostasis and infl ammatory conditions. METHODS: The levels of vaspin, NGAL, apolipoproteins and their correlations with disease activity were compared in 50 psoriatic arthritis patients and 36 healthy controls. RESULTS: The levels of vaspin, NGAL and apolipoprotein B/A1 ratio were signifi cantly higher in the patient group (p < 0.05). Apolipoprotein A1 was lower in the patients with PsA compared to the healthy control group. There was no signifi cant correlation between disease activity and adipokines or metabolic parameters (p > 0.05). CONCLUSION: This is the fi rst study to have compared vaspin and NGAL levels in patients with PsA. Vaspin and NGAL can be used as a biomarker in PsA. Vaspin, NGAL and dyslipoproteinemia are not correlated with disease activity (Tab.

show abstract

“…Overweight and obesity are associated with a systemic low-grade inflammation, which might have influenced our results. Our secondary hypothesis was that we are able to correlate the FOI results with cardiovascular risk factors since these risk factors are well known to be specifically high in Pso/PsA patients [5,[9][10][11][12][13][14][15][16]. However, in our study, only the body weight had an influence on the FOI results.…”

Section: Discussionmentioning

confidence: 90%

“…The increase in mortality seems to be associated with severity of PsA [ 6 ] and disease duration [ 7 , 8 ]. Furthermore, PsA patients reveal an increased prevalence of CV risk factors such as hypertension [ 9 , 10 ], diabetes mellitus [ 6 , 10 ], hyperlipidemia [ 10 , 11 ], and the full metabolic syndrome [ 12 – 16 ]. Accordingly, a significantly increased prevalence of metabolic syndrome in patients with PsA compared to rheumatoid arthritis (RA) patients was demonstrated recently [ 12 ], although comparable inflammatory pathways can be seen in both diseases [ 17 ].…”

Section: Introductionmentioning

confidence: 99%

Detection of subclinical skin manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging

et al. 2020

View full text Add to dashboard Cite

Objectives: To investigate the frequency of subclinical skin inflammation in both hands by fluorescence optical imaging (FOI) in patients with psoriasis/psoriatic arthritis (Pso/PsA) vs. rheumatoid arthritis (RA) and healthy individuals, and to correlate these findings with cardiovascular (CV) risk factors. Patients and methods: The FOI scans were analyzed retrospectively to detect clinically invisible skin enhancement (0-3 scale) in both hands without relationship to underlying joints or blood vessels. We further characterized the FOI patterns and sorted the scans into groups based on the assumed diagnosis (Pso/PsA, RA, and healthy controls), which was compared with the physician's diagnosis. Furthermore, the associations between CV risk factors and imaging findings were investigated by regression analyses. Results: We included FOI scans of patients with Pso/PsA (n = 80), RA (n = 78), and healthy controls (n = 25). Subclinical skin enhancement on the back of their hands was more common in Pso/PsA (72.5%) than in RA patients (20.5%) and healthy individuals (28.0%) (p < 0.001). Based on the FOI pattern, the majority of patients with Pso/PsA (72.5%), RA (76.9%), and healthy controls (68.0%) were classified correctly using the physician-based diagnosis as reference (overall agreement of 74%, kappa = 0.57). No CV risk factors except body weight (kg) were associated with subclinical skin enhancement (OR 1.04, 95% CI 1.02-1.06; p < 0.001). Conclusion: Subclinical subdermal skin inflammation was common in Pso/PsA patients using FOI. Based on the FOI pattern, most patients with Pso/PsA and were classified with the correct diagnosis. We demonstrated an important influence of the body weight on our FOI results. FOI may be a helpful novel tool to study microcirculation in rheumatic diseases with skin involvement.

show abstract

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

Cited by 28 publications

References 33 publications

Detection of subclinical skin manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging

Detection of subclinical skin manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging

Vaspin, neutrophil gelatinase-associated lipocalin and apolipoprotein levels in patients with psoriatic arthritis

Detection of subclinical skin manifestation in patients with psoriasis and psoriatic arthritis by fluorescence optical imaging

Contact Info

Product

Resources

About